These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

161 related items for PubMed ID: 8549379

  • 1. Sparfloxacin empirical therapy in community-acquired pneumonia. Results of a meta-analysis of 2 comparative studies.
    Grassi GG, Brumpt I.
    Drugs; 1995; 49 Suppl 2():406-8. PubMed ID: 8549379
    [No Abstract] [Full Text] [Related]

  • 2. Sparfloxacin for the treatment of community-acquired pneumonia: a pooled data analysis of two studies.
    Aubier M, Lode H, Gialdroni-Grassi G, Huchon G, Hosie J, Legakis N, Regamey C, Segev S, Vester R, Wijnands WJ, Tolstuchow N.
    J Antimicrob Chemother; 1996 May; 37 Suppl A():73-82. PubMed ID: 8737127
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. [New quinolones for the treatment of community-acquired pneumonia--contra].
    Egger M.
    Dtsch Med Wochenschr; 2003 May 09; 128(19):1071. PubMed ID: 12736860
    [No Abstract] [Full Text] [Related]

  • 5. Sparfloxacin versus cefaclor in the treatment of patients with community-acquired pneumonia: a randomized, double-masked, comparative, multicenter study.
    Donowitz GR, Brandon ML, Salisbury JP, Harman CP, Tipping DM, Urick AE, Talbot GH.
    Clin Ther; 1997 May 09; 19(5):936-53. PubMed ID: 9385482
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Comparative efficacy of sparfloxacin in comparison with amoxycillin plus ofloxacin in the treatment of community-acquired pneumonia. French Study Group.
    Portier H, May T, Proust A.
    J Antimicrob Chemother; 1996 May 09; 37 Suppl A():83-91. PubMed ID: 8737128
    [Abstract] [Full Text] [Related]

  • 10. [The role of quinolones in the treatment of community acquired pneumonia].
    Garau J.
    Med Clin (Barc); 1998 Feb 09; 110 Suppl 1():31-5. PubMed ID: 9717158
    [No Abstract] [Full Text] [Related]

  • 11. Safety profile of sparfloxacin, a new fluoroquinolone antibiotic.
    Lipsky BA, Dorr MB, Magner DJ, Talbot GH.
    Clin Ther; 1999 Jan 09; 21(1):148-59. PubMed ID: 10090432
    [Abstract] [Full Text] [Related]

  • 12. New antibiotic approved for community-acquired infections.
    Nurse Pract; 1998 Jan 09; 23(1):94. PubMed ID: 9470200
    [No Abstract] [Full Text] [Related]

  • 13. A review of worldwide experience with sparfloxacin in the treatment of community-acquired pneumonia and acute bacterial exacerbations of chronic bronchitis.
    Finch RG.
    Int J Antimicrob Agents; 1999 Jun 09; 12(1):5-17. PubMed ID: 10389642
    [Abstract] [Full Text] [Related]

  • 14. Pharmacokinetics-pharmacodynamics of quinolones against Streptococcus pneumoniae in patients with community-acquired pneumonia.
    Bhavnani SM, Forrest A, Hammel JP, Drusano GL, Rubino CM, Ambrose PG.
    Diagn Microbiol Infect Dis; 2008 Sep 09; 62(1):99-101. PubMed ID: 18583085
    [Abstract] [Full Text] [Related]

  • 15. Safety profile of sparfloxacin in the treatment of respiratory tract infections.
    Rubinstein E.
    J Antimicrob Chemother; 1996 May 09; 37 Suppl A():145-60. PubMed ID: 8737134
    [Abstract] [Full Text] [Related]

  • 16. Clinical implications and treatment of multiresistant Streptococcus pneumoniae pneumonia.
    File TM.
    Clin Microbiol Infect; 2006 May 09; 12 Suppl 3():31-41. PubMed ID: 16669927
    [Abstract] [Full Text] [Related]

  • 17. A clinical solution to antimicrobial resistance in community-acquired pneumonia: narrowing the spectrum of antimicrobial therapy: comment on "Current and potential usefulness of pneumococcal urinary antigen detection in hospitalized patients with community-acquired pneumonia to guide antimicrobial therapy".
    Yu VL.
    Arch Intern Med; 2011 Jan 24; 171(2):172-3. PubMed ID: 21263107
    [No Abstract] [Full Text] [Related]

  • 18. Treatment of community-acquired pneumonia: a randomized comparison of sparfloxacin, amoxycillin-clavulanic acid and erythromycin.
    Lode H, Garau J, Grassi C, Hosie J, Huchon G, Legakis N, Segev S, Wijnands G.
    Eur Respir J; 1995 Dec 24; 8(12):1999-2007. PubMed ID: 8666093
    [Abstract] [Full Text] [Related]

  • 19. Efficacy and safety of grepafloxacin 600 mg daily for 10 days in patients with community-acquired pneumonia.
    Topkis S, Swarz H, Breisch SA, Maroli AN.
    Clin Ther; 1997 Dec 24; 19(5):975-88. PubMed ID: 9385485
    [Abstract] [Full Text] [Related]

  • 20. New generations of quinolones: with particular attention to levofloxacin.
    Ambrose PG, Owens RC, Quintiliani R, Nightingale CH.
    Conn Med; 1997 May 24; 61(5):269-72. PubMed ID: 9197076
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.